These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J; Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936 [TBL] [Abstract][Full Text] [Related]
6. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R; Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390 [TBL] [Abstract][Full Text] [Related]
9. [Special features of clinical effects of an angiotensin converting enzyme inhibitor lisinopril in patients with arterial hypertension]. Britov AN; Alamdarova II; Deev AD; Orlov AA Kardiologiia; 2003; 43(10):66-71. PubMed ID: 14748343 [No Abstract] [Full Text] [Related]
10. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Strauss MH; Lonn EM; Verma S Eur Heart J; 2005 Nov; 26(22):2351-3. PubMed ID: 16219656 [No Abstract] [Full Text] [Related]
11. Hypertension strategies in the third millennium: conservatism, evidence and the folly of speculation. McIntyre HF Int J Clin Pract; 2009 Jan; 63(1):7-14. PubMed ID: 19125987 [No Abstract] [Full Text] [Related]
12. [No bluff to be discovered in clinical trials]. Berglund T Lakartidningen; 2009 Mar 25-31; 106(13):952-3. PubMed ID: 19441200 [No Abstract] [Full Text] [Related]
13. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Onuigbo MA Arch Intern Med; 2009 Oct; 169(19):1810; author reply 1810-1. PubMed ID: 19858442 [No Abstract] [Full Text] [Related]
14. [What are the sequelae of the ALLHAT Study?]. Vetter W; Dtsch Med Wochenschr; 2003 Mar; 128(13):687. PubMed ID: 12698959 [No Abstract] [Full Text] [Related]
15. [Evidence-based usefulness of Ca antagonists and ACEIs and ARBs for the primary and secondary prevention of major cardiovascular and renal events in patients with hypertension]. Fujino T; Hasebe N; Kikuchi K Clin Calcium; 2005 Oct; 15(10):1695-708. PubMed ID: 16199917 [TBL] [Abstract][Full Text] [Related]
17. Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. Eveson DJ; Robinson TG; Potter JF Am J Hypertens; 2007 Mar; 20(3):270-7. PubMed ID: 17324738 [TBL] [Abstract][Full Text] [Related]
18. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U; Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186 [TBL] [Abstract][Full Text] [Related]
19. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved. Probstfield J J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849 [No Abstract] [Full Text] [Related]
20. Strengths and weaknesses of drug trials without controls. Bulpitt CJ J Cardiovasc Pharmacol; 1997 Nov; 30(5):545-6; discussion 547. PubMed ID: 9388034 [No Abstract] [Full Text] [Related] [Next] [New Search]